OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
OptimizeRx CorporationNASDAQ: OPRX
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $19.84M fell 9.5% year over year, behind the +13.8% change in trailing-twelve-month revenue. Sequentially, it fell 38.4% from the prior quarter. Over 3 fiscal years it compounded at +20.6% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $88.86M (-18.8%) for the fiscal year ending Dec 2026, a slowdown from the +18.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $19.84M-38.4% QoQ
- Last fiscal yearDec 2025
- $109.43M+18.8% YoY
- LTMMar 2026
- $107.35M+13.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.5% | -30.8% | -21.3 pp |
| 1 year | +18.8% | -18.8% | -37.6 pp |
| 3-year CAGR | +20.6% | -2.9% | -23.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 109.43M USD
- Year-over-year change
- +18.8%
- 4-year CAGR
- +15.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109.43M | +18.8% |
| FY2024 | 2024-12-31 | 92.13M | +28.8% |
| FY2023 | 2023-12-31 | 71.52M | +14.5% |
| FY2022 | 2022-12-31 | 62.45M | +1.9% |
| FY2021 | 2021-12-31 | 61.29M | — |
Revenue vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +13.8% is the 3rd highest of 9, against a peer median of -1.1%.
- Over three fiscal years its annual growth of +20.6% compares with a peer median of +2.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $345.9M USD | -0.5% | +2.0% | |
| LTM Mar 2026 | $238.26M USD | -3.9% | +2.7% | |
| LTM Mar 2026 | $138.64M USD | -1.9% | -3.2% | |
| LTM Mar 2026 | $136.64M USD | -1.7% | +1.3% | |
| LTM Mar 2026 | $127.48M USD | -19.5% | +40.0% | |
| LTM Mar 2026 | $107.35M USD | +13.8% | +20.6% | |
| LTM Mar 2026 | $81.18M USD | +20.9% | +17.6% | |
| LTM Feb 2026 | $80.54M USD | +2.5% | +13.7% | |
| LTM Mar 2026 | $3.92M USD | +58.6% | -21.7% | |
| LTM Mar 2026 | CA$0 CAD | — | — | |
| Peer median (excluding OPRX) | — | -1.1% | +2.4% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 61.29M | 62.45M | 71.52M | 92.13M | 109.43M |
| Cost of Revenue | 25.65M | 23.48M | 28.62M | 32.75M | 40.16M |
| Gross Profit | 35.64M | 38.97M | 42.9M | 59.38M | 69.27M |
| Gross Margin | 58.1% | 62.4% | 60.0% | 64.5% | 63.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 33.19M | 49.24M | 58.02M | 61.27M | 50.25M |
| Operating Expenses | 35.28M | 51.26M | 69.3M | 73.08M | 57.21M |
| Depreciation & Amortization | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M |
| EBITDA | 2.34M | (9.42M) | (21.31M) | (8.9M) | 16.57M |
| EBITDA Margin | 3.8% | -15.1% | -29.8% | -9.7% | 15.1% |
| Operating Income | 361.1K | (12.29M) | (26.4M) | (13.71M) | 12.06M |
| Operating Margin | 0.6% | -19.7% | -36.9% | -14.9% | 11.0% |
| Interest Income | 16.98K | 852.3K | 2.19M | 329K | 353K |
| Interest Expense | 0 | 0 | 1.45M | 6.16M | 5.29M |
| Other Income / Expenses | 16.98K | 852.3K | 1.24M | (5.68M) | (5.11M) |
| Income Before Tax | 378.08K | (11.44M) | (25.16M) | (19.39M) | 6.95M |
| Pre-Tax Margin | 0.6% | -18.3% | -35.2% | -21.0% | 6.4% |
| Income Tax Expense | 0 | 0 | (7.6M) | 725K | 1.82M |
| Net Income | 378.08K | (11.44M) | (17.57M) | (20.11M) | 5.13M |
| Net Margin | 0.6% | -18.3% | -24.6% | -21.8% | 4.7% |
| EPS (Basic) | 0.02 | (0.64) | (1.03) | (1.10) | 0.28 |
| EPS (Diluted) | 0.02 | (0.64) | (1.03) | (1.10) | 0.27 |
| Weighted Avg Shares | 17.23M | 17.78M | 17.12M | 18.29M | 18.56M |
| Weighted Avg Shares (Diluted) | 17.69M | 17.78M | 17.12M | 18.29M | 19M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.